INFLUVAC TETRA 15 MCG / 0.5 ML
HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML · DIN 02484854 · BGP PHARMA ULC
Health Canada status: MARKETED
What is INFLUVAC TETRA?
INFLUVAC TETRA 15 MCG / 0.5 ML contains HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02484854, held by BGP PHARMA ULC, supplied as SUSPENSION for SUBCUTANEOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 17-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is INFLUVAC TETRA used for?
Prevention of influenza infection caused by the specific strains contained in the vaccine, in adults and children from 6 months of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02484854 |
|---|---|
| Brand name | INFLUVAC TETRA |
| Generic / active ingredient | HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML |
| Manufacturer | BGP PHARMA ULC |
| Strength | 15 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | SUBCUTANEOUS ; INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Oct-2019 |
| Original market date | 2019-10-17 00:00:00 |
How is it administered?
Adults and children ≥6 months: 0.5 mL. Unprimed children <9 years: second 0.5 mL dose after ≥4 weeks. Administer by IM or deep SC injection. Shake well before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (section 11 header present but content missing), though standard vaccine handling is implied.
How is it supplied?
0.5 mL pre-filled single-dose syringes (glass, type I) with or without a needle. Available in packs of 1 or 10.
Contraindications
Hypersensitivity to active substances, eggs, chicken protein, formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin. Defer in presence of febrile illness or acute infection.
Warnings and precautions
Do not use if allergic to eggs or vaccine components. Not for intravascular use. Potential for anaphylaxis; keep epinephrine available. Risk of GBS if occurred within 6 weeks of previous flu vaccine.
What can be used instead?
Other Canadian products sharing ATC code J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN. 8 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AREPANRIX H5N1 | 3.75 MCG / 0.5 ML | EMULSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02401886 |
| FLUAD | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | DIN 02362384 |
| FLUCELVAX | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | DIN 02553708 |
| FLUVIRAL | 15 MCG / 0.5 ML | SUSPENSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02420686 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365936 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365707 |
| FLUZONE HIGH-DOSE | 60 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02445646 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473283 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473313 |
| AGRIFLU | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | CANCELLED PRE MARKET | DIN 02346850 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.